[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100323993":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":20,"locations":21,"responsibleParty":81,"collaborators":20,"id":83,"slug":84,"hasResults":85,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":89,"eligibilityCriteria":90,"healthyVolunteers":85,"sex":91,"minAge":92,"maxAge":20,"enrollmentInfo":93,"targetDuration":20,"studyType":96,"phases":97,"briefSummary":100,"conditions":101,"keywords":20,"overallStatus":103,"whyStopped":20,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":112},{"fullName":5,"class":6},"Nantes University Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"ARM experimental","EXPERIMENTAL","All the patients will have MIBI-Tc99m\u002FIodine-123 . Following the injections they will have a scintigraphy.",[13],"Drug: MIBI-Tc99m\u002FIodine-123",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","MIBI-Tc99m\u002FIodine-123","Following the injection of MIBI-Tc99m\u002FIodine-123 , the patients will have a scintigraphy.",[9],null,[22,34,43,50,59,66,75],{"facility":23,"status":20,"city":24,"state":20,"zip":25,"country":26,"countryCode":27,"cosmosGeoPoint":28,"geoPoint":33,"contacts":20},"hopital Avicenne","Bobigny","93000","France","FR",{"type":29,"coordinates":30},"Point",[31,32],2.45012,48.90982,{"lat":32,"lon":31},{"facility":35,"status":20,"city":36,"state":20,"zip":37,"country":26,"countryCode":27,"cosmosGeoPoint":38,"geoPoint":42,"contacts":20},"CHU","Lille","59000",{"type":29,"coordinates":39},[40,41],3.05512,50.63391,{"lat":41,"lon":40},{"facility":35,"status":20,"city":44,"state":20,"zip":20,"country":26,"countryCode":27,"cosmosGeoPoint":45,"geoPoint":49,"contacts":20},"Limoges",{"type":29,"coordinates":46},[47,48],1.24759,45.83362,{"lat":48,"lon":47},{"facility":51,"status":20,"city":52,"state":20,"zip":53,"country":26,"countryCode":27,"cosmosGeoPoint":54,"geoPoint":58,"contacts":20},"Hospices Civils","Lyon","69000",{"type":29,"coordinates":55},[56,57],4.84789,45.74906,{"lat":57,"lon":56},{"facility":35,"status":20,"city":60,"state":20,"zip":20,"country":26,"countryCode":27,"cosmosGeoPoint":61,"geoPoint":65,"contacts":20},"Nantes",{"type":29,"coordinates":62},[63,64],-1.55336,47.21725,{"lat":64,"lon":63},{"facility":67,"status":20,"city":68,"state":20,"zip":69,"country":26,"countryCode":27,"cosmosGeoPoint":70,"geoPoint":74,"contacts":20},"Assistance publique des Hôpitaux de Paris","Paris","75 000",{"type":29,"coordinates":71},[72,73],2.3488,48.85341,{"lat":73,"lon":72},{"facility":76,"status":20,"city":68,"state":20,"zip":77,"country":26,"countryCode":27,"cosmosGeoPoint":78,"geoPoint":80,"contacts":20},"Institut Curie","75005",{"type":29,"coordinates":79},[72,73],{"lat":73,"lon":72},{"type":82,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100323993","phase-2-value-of-the-combination-ultrasonography-with-ti-rads-score--dual-tracer-scintigraphy-mibi-tc99miodine-123-in-the-detection-of-malignancy-of-thyroid-nodules-15-mm-classified-bethesda-iii-or-iv-on-cytology-100323993",false,"NCT03498183","Value of the Combination Ultrasonography With Ti-RADS Score \u002F Dual Tracer Scintigraphy MIBI-Tc99m\u002FIodine-123 in the Detection of Malignancy of Thyroid Nodules (≥15 mm) Classified Bethesda III or IV on Cytology","Value of the Combination Ultrasonography With Ti-RADS Score \u002F Dual Tracer Scintigraphy MIBI-Tc99m\u002FIodine-123 in the Detection of Malignancy of Thyroid Nodules (Sup or Egal to 15 mm) Classified Bethesda III or IV on Cytology","MIBI-THYR","Inclusion Criteria:\n\n* Any patient over 18 years with a thyroid nodule ≥15 mm (maximal diameter measured on US) with a Bethesda class III or IV (FNA less than 6 months before the surgery).\n* Given signed, written informed consent\n* Affiliation to a social security system.\n* Neither-pregnant nor breast-feeding women.\n* Use of efficient contraception for patient with pregnancy potential (if needed).\n\nExclusion Criteria:\n\n* Underage and adults under guardianship.\n* Pregnant, without efficient contraception (if needed) or breast feeding women.\n* Administration of iodinated contrast in the previous 3 weeks.\n* Contraindication to scintigraphy or to Iodine123\u002F MIBI 99Tc administration\n* Treatment containing iodine (i.e. : Amiodarone)\n* Hypo or hyperthyroidism treated or not.\n* Nodules inferior 15 mm.\n* Refusal to sign the consent.\n* Refusal of surgical treatment or contraindication for surgery or anesthesia\n* Morbid obesity (BMI Superior 40 kg\u002Fm2).\n* Hyperparathyroidism.\n* History of cervicotomy.","ALL","18 Years",{"count":94,"type":95},372,"ACTUAL","INTERVENTIONAL",[98,99],"PHASE2","PHASE3","The main objective of the study is to show that the addition of ultrasonography to the dual tracer scintigraphy MIBI-Tc99m\u002FIodine-123 will increase (at least +5%) the negative predictive value compared to the dual tracer scintigraphy alone in detection of malignancy in thyroid nodules ≥15 mm classified as Bethesda III-IV on cytology.",[102],"Malignancy of Thyroid Nodules","COMPLETED","2025-06-03",{"date":106,"type":95},"2025-06-06",{"date":108,"type":95},"2019-01-17",{"date":110,"type":95},"2025-05-07",{"name":5,"class":6},7]